432 related articles for article (PubMed ID: 32666675)
1. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors.
Li W; Deng R; Liu S; Wang K; Sun J
Liver Int; 2020 Oct; 40(10):2316-2325. PubMed ID: 32666675
[TBL] [Abstract][Full Text] [Related]
2. Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma.
Wu JW; Kao JH; Tseng TC
Clin Mol Hepatol; 2021 Oct; 27(4):524-534. PubMed ID: 33618507
[TBL] [Abstract][Full Text] [Related]
3. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral.
Chang KC; Lin MT; Wang JH; Hung CH; Chen CH; Chiu SY; Hu TH
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560675
[TBL] [Abstract][Full Text] [Related]
4. Liver Carcinogenesis Suppression in Chronic Hepatitis B in the Nucleoside Analogues Era.
Nishikawa H; Kim SK; Asai A
In Vivo; 2024; 38(1):40-47. PubMed ID: 38148074
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus core-related antigen (HBcrAg) as a prognostic marker for the development of hepatocellular carcinoma: A mini systematic review of the literature.
Afifi AM; Elgenidy A; Hashim M; Awad AK; Jalal PK
Rev Med Virol; 2022 Nov; 32(6):e2353. PubMed ID: 35441759
[TBL] [Abstract][Full Text] [Related]
7. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH
Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004
[TBL] [Abstract][Full Text] [Related]
8. Incidence of development of hepatocellular carcinoma in Japanese patients infected with hepatitis B virus is equivalent between genotype B and C in long term.
Haga H; Saito T; Okumoto K; Tomita K; Katsumi T; Mizuno K; Nishina T; Watanabe H; Ueno Y
J Viral Hepat; 2019 Jul; 26(7):866-872. PubMed ID: 30924226
[TBL] [Abstract][Full Text] [Related]
9. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy.
Liu S; Deng R; Zhou B; Liang X; Liu Z; Peng J; Chen J; Zhou Y; Guo Y; Chen Y; Li W; Shen S; Lu X; Zhao S; Liao X; Liang H; Lan Y; Hou J; Fan R; Sun J
J Infect Dis; 2022 Sep; 226(5):881-890. PubMed ID: 34931674
[TBL] [Abstract][Full Text] [Related]
10. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma.
Urata Y; Kubo S; Takemura S; Uenishi T; Kodai S; Shinkawa H; Sakae M; Kaneda K; Ohata K; Nozawa A; Suehiro S
J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):685-96. PubMed ID: 22203455
[TBL] [Abstract][Full Text] [Related]
11. [Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention].
Han C; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):293-296. PubMed ID: 33979951
[TBL] [Abstract][Full Text] [Related]
12. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
Choi WM; Kim GA; Choi J; Choi GH; Lee YB; Sinn DH; Lim YS
Gut; 2024 Mar; 73(4):649-658. PubMed ID: 37813567
[TBL] [Abstract][Full Text] [Related]
13. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
[TBL] [Abstract][Full Text] [Related]
14. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
[TBL] [Abstract][Full Text] [Related]
15. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
J Hepatol; 2016 Jul; 65(1):48-56. PubMed ID: 27034253
[TBL] [Abstract][Full Text] [Related]
16. Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection.
Lin CL; Kao JH
Clin Mol Hepatol; 2023 Jul; 29(3):605-622. PubMed ID: 36788759
[TBL] [Abstract][Full Text] [Related]
17. Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma.
Wei Q; Xu X; Ling Q; Zhou B; Zheng SS
Hepatobiliary Pancreat Dis Int; 2013 Jun; 12(3):251-5. PubMed ID: 23742769
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
Honda M; Shirasaki T; Terashima T; Kawaguchi K; Nakamura M; Oishi N; Wang X; Shimakami T; Okada H; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Infect Dis; 2016 Apr; 213(7):1096-106. PubMed ID: 26621908
[TBL] [Abstract][Full Text] [Related]
19. Review article: the prevention of hepatitis B-related hepatocellular carcinoma.
Lin CL; Kao JH
Aliment Pharmacol Ther; 2018 Jul; 48(1):5-14. PubMed ID: 29722445
[TBL] [Abstract][Full Text] [Related]
20. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma.
Chong CC; Wong GL; Lai PB
World J Gastroenterol; 2014 May; 20(20):6006-12. PubMed ID: 24876723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
